Bonney Family Foundation Inc.

The Bonney Family Foundation concentrates its giving in three primary areas: higher education capital investment, STEM education and research facilities, and biomedical research support. The foundation's signature grants have been directed to Bates College in Lewiston, Maine — the alma mater of both Michael and Alison Bonney (Class of 1980), where four generations of the Bonney family have attended. The foundation's $50 million gift in 2017 funded the Bonney Center for Science, providing new and renovated STEM facilities that opened in fall 2021, and represented one of the largest gifts ever to a Maine institution. A prior $10 million gift in 2016 endowed three professorships and launched a new program in Digital and Computational Studies. Beyond Bates, Michael Bonney serves on the board of the Whitehead Institute for Biomedical Research at MIT, reflecting the foundation's interest in connecting world-class science with commercialization pathways — a priority he has articulated publicly, noting the importance of alternative research funding sources amid reduced federal support. The foundation operates as a preselected-only grantmaker with no public application process, directing funds exclusively to institutions with which the family has established deep relationships. Michael W. Bonney brings a distinctive blend of pharmaceutical industry expertise and deep institutional loyalty to the foundation's grantmaking. His career trajectory — from Hannaford Brothers pharmacy operations in Maine, through 11 years at Zeneca Pharmaceuticals and 6 years at Biogen, to the Cubist CEO role — informs the foundation's emphasis on STEM education and biomedical research infrastructure.

The Bonney Family Foundation's financial profile reveals a deliberate spend-down trajectory from its 2015 peak. After receiving approximately $40 million in contributions (coinciding with the Cubist Pharmaceuticals acquisition by Merck for $9.5 billion), total assets reached $40.5 million that year. Since then, the foundation has consistently distributed more than it receives: in fiscal year 2024, it disbursed $4.5 million in charitable grants against only $2.1 million in total revenue (sourced from investment asset sales at $1.56M, dividends at $427K, and contributions at $104K), resulting in a net decline of $2.5 million. At the current rate of approximately $3-5 million in annual net asset reduction, the foundation's remaining $16.6 million in assets could sustain grantmaking for roughly 4-6 more years without new contributions. This pattern is consistent with a giving-while-living philosophy common among pharmaceutical-wealth family foundations, where founders prefer to see the impact of their giving within their lifetimes rather than creating a perpetual endowment. The foundation maintains zero liabilities and keeps its operational costs negligible, with virtually all expenses flowing directly to charitable disbursements. Revenue is derived primarily from asset sales (74.6%), dividends (20.4%), and contributions (4.9%). The foundation has been tax-exempt under Section 501(c)(3) since March 2002.

The Bonney Family Foundation occupies a distinctive niche among Massachusetts-based pharmaceutical-wealth family foundations. The following comparison contextualizes its grantmaking approach:

The Bonney Foundation is notable for its exceptionally high payout rate (27% of assets annually vs. the 5% minimum required), its near-exclusive focus on a single alma mater institution, and its apparent spend-down trajectory. Among pharma-wealth foundations of comparable size, it is unusually concentrated in its beneficiary selection, channeling most resources to Bates College rather than distributing across multiple institutions. This concentration strategy has enabled genuinely transformational gifts — the $50M Bonney Center gift was one of the largest ever to a liberal arts college — but limits diversification and reduces opportunities for external grant-seekers.

The Bonney Family Foundation Inc. is a private independent foundation based in Framingham, Massachusetts, established in 2002 by Michael W. Bonney and Alison Grott Bonney. As of its most recent fiscal year (2024), the foundation holds $16.6 million in total assets and distributed $4.5 million in charitable disbursements — representing 97% of its total expenses. The foundation received a transformational $40 million contribution in 2015, likely tied to proceeds from the Cubist-Merck acquisition, and has since been distributing at an accelerated pace of $3-7 million annually. Both Michael (President) and Alison (Treasurer/Clerk) serve as unpaid officers. Beyond the foundation, Bonney chairs the boards of Alnylam Pharmaceuticals and Bates College, and has served on the boards of Celgene Corporation and the Whitehead Institute for Biomedical Research. He has been recognized with the Massachusetts Biotechnology Council's Innovative Leadership Award. The Bonneys have articulated their giving philosophy as rooted in gratitude, describing the intersection of donor passion with institutional priorities as magical and joyous. They emphasize an obligation to improve communities where they have lived and a conviction that liberal arts education is increasingly critical to society.

The Bonney Family Foundation does not accept unsolicited proposals and has no public application process. Grants are directed entirely by the family trustees toward institutions with which they have established deep, multi-generational relationships. For organizations seeking to engage the foundation, the most viable pathway is through institutional relationship-building with Michael or Alison Bonney via their board affiliations (Bates College, Alnylam Pharmaceuticals, Whitehead Institute). The foundation's grantmaking is heavily concentrated on Bates College and biomedical research institutions in the greater Boston area. Given the foundation's apparent spend-down trajectory (assets declining from $40.5M to $16.6M over nine years), the window for new institutional relationships may be narrowing. Organizations aligned with STEM education, liberal arts higher education, or biomedical research commercialization would have the strongest thematic fit, but the preselected-only model means cold outreach is unlikely to succeed. The foundation's website (bonney.org) redirects to a personal contact page and provides no grant program information or guidelines.